Association of apolipoprotein e genotypes with lipid levels and coronary risk

JAMA

Volumn 298, Issue 11, 2007, Pages 1300-1311

  Bennet, Anna M ^a   Di Angelantonio, Emanuele ^a   Ye, Zheng ^a   Wensley, Frances ^a   Dahlin, Anette ^b   Ahlbom, Anders ^b   Keavney, Bernard ^d   Collins, Rory ^e   Wiman, Björn ^b   De Faire, Ulf ^b,c   Danesh, John ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; BIOSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; EMBASE; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDLINE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SCISEARCH; BLOOD; CLINICAL TRIAL; GENETICS; META ANALYSIS; RISK ASSESSMENT;

APOLIPOPROTEINS E; CHOLESTEROL, LDL; CORONARY DISEASE; GENOTYPE; HUMANS; LIPIDS; RISK ASSESSMENT;

EID: 34548736492     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.11.1300     Document Type: Review

References (183)

1. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155(6):487-495.
2. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622-630.
3. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet. 1980;32(3):339-347.
4. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res. 1992;33(4):447-454.
5. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141(2):137-147.
6. Ioannidis JPA, Trikalinos TA, Khoury MJ. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol. 2006;164(7):609-614.
7. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large vs small studies: an empirical assessment. Lancet. 2003;361(9357):567-571.
8. Khoury MJ, Little J, Gwinn M, Ioannidis JP. On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies. Int J Epidemiol. 2007;36(2):439-445.
9. Little J, Bradley L, Bray MS, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 2002;156(4):300-310.
10. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90(1):583-612.
11. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol. 2006;164(10):921-935.
12. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C - > T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331(7524):1053.
13. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. Lancet. 2004;363(9410):689-695.
14. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls. Lancet. 2006;367(9511):651-658.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
17. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
19. Bai X, Zhao M, Wang B. Dyslipidemia-related risk factors for myocardial infarction and polymorphism of ApoE gene among myocardial infarction patients and their siblings [in Chinese]. Zhonghua Yi Xue Za Zhi. 2001;81(6):340-343.
20. Banares VG, Peterson G, Aguilar D, et al. Association between the APOE*4 allele and atherosclerosis is age dependent among Argentine males. Hum Biol. 2005;77(2):247-256.
21. Batalla A, Alvarez R, Reguero JR, et al. Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphisms in the risk for early myocardial infarction. Clin Chem. 2000;46(12):1910-1915.
22. Brouwer DA, Leerink CB, Steward HN, et al. Lipids, apolipoprotein-E genotypes and other risk factors of patients with coronary artery disease in Curacao. West Indian Med J. 1997;46(2):47-52.
23. Dart A, Sherrard B, Simpson H. Influence of apoE phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease. Atherosclerosis. 1997;130(1-2):161-170.
24. Djousse L, Myers RH, Province MA, et al. Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke. 2002;33(5):1357-1361.
25. Frikke-Schmidt R, Tybjaerg-Hansen A, Steffensen R, Jensen G, Nordestgaard BG. Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol. 2000;35(5):1192-1199.
26. Gerdes LU, Klausen IC, Sihm I, Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol. 1992;9(3):155-167.
27. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med. 2000;343(11):774-780.
28. Gong W, Peng S, Peng J, Wang J. Association of geriatric coronary heart disease with apolipoprotein E gene polymorphism in relation and its impact on serum lipid levels. Chin J Gerontol. 2000;5:149-150.
29. Heijmans BT, Slagboom PE, Gussekloo J, et al. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am J Med Genet. 2002;107(3):201-208.
30. Inbal A, Freimark D, Modan B, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood. 1999;93(7):2186-2190.
31. Isbir T, Yilmaz H, Agachan B, Karaali ZE. Cholesterol ester transfer protein, apolipoprotein E and lipoprotein lipase genotypes in patients with coronary artery disease in the Turkish population. Clin Genet. 2003;64(3):228-234.
32. Jin W, Lu YS, Xu YH, Zheng MF. Relation of apolipoprotein E polymorphism to myocardial infarction and serum lipids. Shanghai Med J (Chin). 1998;21:697-699.
33. Joven J, Simo JM, Vilella E, et al. Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction. Atherosclerosis. 1998;140(1):155-159.
34. Kardaun JW, White L, Resnick HE, et al. Genotypes and phenotypes for apolipoprotein E and Alzheimer disease in the Honolulu-Asia aging study. Clin Chem. 2000;46(10):1548-1554.
35. Kataoka S, Robbins DC, Cowan LD, et al. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 1996;16(8):918-925.
36. Katsuya T, Baba S, Ishikawa K, et al. Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study. J Hypertens. 2002;20(10):2017-2021.
37. Keavney B, Palmer A, Parish S, et al. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol. 2004;33(5):1002-1013.
38. Kharrazi H, Vaisi Raygani A, Sabokroh AR, Pour-motabbed T. Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. Clin Biochem. 2006;39(6):613-616.
39. Kolovou G, Yiannakouris N, Hatzivassiliou M, et al. Association of apolipoprotein E polymorphism with myocardial infarction in Greek patients with coronary artery disease. Curr Med Res Opin. 2002;18(3):118-124.
40. Kolovou GD, Daskalova DC, Hatzivassiliou M, et al. The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population - implications for the interpretation of similar studies. Angiology. 2003;54(1):51-58.
41. Letonja M, Guzic-Salobir B, Peterlin B, Petrovic D. Apolipoprotein E gene polymorphism effects triglycerides but not CAD risk in Caucasian women younger than 65 years. Ann Genet. 2004;47(2):147-153.
42. Li WH, Huang DJ, Du XH, Zhang WZ, Hu JL. Effect of apolipoprotein E polymorphisms on serum lipids and relation to coronary heart stenosis. Chin J Arterioscl (Chin). 2000;8:54-57.
43. Licastro F, Chiappelli M, Caldarera CM, et al. The concomitant presence of polymorphic alleles of interleukin-1beta, interleukin-6 and apolipoprotein E is associated with an increased risk of myocardial infarction in elderly men: results from a pilot study. Mech Ageing Dev. 2004;125(8):575-579.
44. Luc G, Bard JM, Arveiler D, et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: the ECTIM Study. Arterioscler Thromb. 1994;14(9):1412-1419.
45. März W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J. 2004;25(23):2109-2119.
46. Mansur AP, Annicchino-Bizzacchi J, Favarato D, Avakian SD, Cesar LA, Ramires JA. Angiotensin-converting enzyme and apolipoproteins genes polymorphism in coronary artery disease. Clin Cardiol. 2000;23(5):335-340.
47. Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Perret B, Ferrieres J. Effect of apolipoprotein E alleles and angiotensin-converting enzyme insertion/deletion polymorphisms on lipid and lipoprotein markers in middle-aged men and in patients with stable angina pectoris or healed myocardial infarction. Am J Cardiol. 2003;92(9):1102-1105.
48. Menzel HJ, Kladetzky RG, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arterioscl. 1983;3(4):310-315.
49. Nakai K, Fusazaki T, Zhang T, et al. Polymorphism of the apolipoprotein E and angiotensin I converting enzyme genes in Japanese patients with myocardial infarction. Coron Artery Dis. 1998;9(6):329-334.
50. Oh JY, Barrett-Connor E. Apolipoprotein E polymorphism and lipid levels differ by gender and family history of diabetes: the Rancho Bernardo Study. Clin Genet. 2001;60(2):132-137.
51. Orth M, Weng W, Funke H, et al. Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28→Pro), on lipoproteins and the prevalence of coronary artery disease in whites. Arterioscler Thromb Vasc Biol. 1999;19(5):1306-1315.
52. Orth M, Dierkes J, Luley C. Chylomicron remnant concentrations in patients with coronary artery disease. Clin Chem Lab Med. 2003;41(5):652-662.
53. Ou T, Yamakawa-Kobayashi K, Arinami T, et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis. 1998;137(1):23-28.
54. Pablos-Méndez A, Mayeux R, Ngai C, Shea S, Berglund L. Association of apoE polymorphism with plasma lipid levels in a multiethnic elderly population. Arterioscler Thromb Vasc Biol. 1997;17(12):3534-3541.
55. Peng DQ, Zhao SP, Nie S, Li J. Gene-gene interaction of PPARgamma and ApoE affects coronary heart disease risk. Int J Cardiol. 2003;92(2-3):257-263.
56. Peng S, Peng J, Gong WX. Association of apolipoprotein E gene polymorphism with early-onset coronary heart disease and its effect on plasma lipid levels [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2001;18(5):375-378.
57. Raslova K, Smolkova B, Vohnout B, Gasparovic J, Frohlich JJ. Risk factors for atherosclerosis in survivors of myocardial infarction and their spouses: comparison to controls without personal and family history of atherosclerosis. Metabolism. 2001;50(1):24-29.
58. Regis-Bailly A, Visvikis S, Steinmetz J, et al. Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Clin Genet. 1996;50(5):339-347.
59. Bennet AM, van Maarle MC, Hallqvist J, et al. Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction. Atherosclerosis. 2006;187(2):408-414.
60. Scaglione L, Bergerone S, Gambino R, et al. Role of lipid, apolipoprotein levels and apolipoprotein E genotype in young Italian patients with myocardial infarction. Nutr Metab Cardiovasc Dis. 1999;9(3):118-124.
61. Scuteri A, Najjar SS, Muller D, et al. ApoE4 allele and the natural history of cardiovascular risk factors. Am J Physiol Endocrinol Metab. 2005;289(2):E322-E327.
62. Slooter AJ, Cruts M, Hofman A, et al. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. Neurology. 2004;62(7):1196-1198.
63. Sturgeon JD, Folsom AR, Bray MS, Boerwinkle E, Ballantyne CM. Apolipoprotein E genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study. Stroke. 2005;36(11):2484-2486.
64. Terry JG, Howard G, Mercuri M, Bond MG, Crouse JR III. Apolipoprotein E polymorphism is associated with segment-specific extracranial carotid artery intima-media thickening. Stroke. 1996;27(10):1755-1759.
65. von Muhlen D, Barrett-Connor E, Kritz-Silverstein D. Apolipoprotein E genotype and response of lipid levels to postmenopausal estrogen use. Atherosclerosis. 2002;161(1):209-214.
66. Wang GQ, Wang XL, Yang CR, Li X, Xiao BY, Zhang YZ. Relationship between apolipoprotein E gene polymorphism and longevity, lipids in Uygru nationality. Chin J Gerontol (Chin). 2001;5:325-327.
67. Wang XH, Gao HQ. Clinical study of the association between apoE polymorphism and lipid metabolism of patients with CHD. J Clin Cardiol (Chin). 2000;16:440-442.
68. Wu JH, Lo SK, Wen MS, Kao JT. Characterization of apolipoprotein E genetic variations in Taiwanese: association with coronary heart disease and plasma lipid levels. Hum Biol. 2002;74(1):25-31.
69. Boer JM, Ehnholm C, Menzel HJ, et al. Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol. 1997;17(9):1675-1681.
70. Chen Z, Huang J, Zhu TB, et al. Study on the lipids and apolipoprotein E polymorphism in siblings and offspring of patients with coronary heart disease aged 55 years or younger. J Clin Cardiol (Chin). 2002;18:150-152.
71. Choi YH, Kim JH, Kim DK, et al. Distributions of ACE and APOE polymorphisms and their relations with dementia status in Korean centenarians. J Gerontol A Biol Sci Med Sci. 2003;58(3):227-231.
72. Cui JB, Wang SJ, Wang JP, et al. The relationship between apolipoprotein E genotypes and levels of plasma lipids in the Henan Han population. J Henan Med Uni (Chin). 2000;35:519-522.
73. Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology. 2005;64(9):1531-1538.
74. Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 1986;27(3):227-235.
75. Fan P, Zhang ZH, Liu Y, Gu HQ, Liu BW. Apolipoprotein E polymorphism, serum lipids and apolipoproteins of 362 Han national subjects in Chengdu area [in Chinese]. Hua Xi Yi Ke Da Xue Xue Bao. 1999;30(4):373-374.
76. Guo Y, Guo JJ, Nao JF, Wang FW. The relations between polymorphisms of apolipoprotein E gene and atherosclerotic cerebral infarction. Chinese J Neurol (Chin). 1997;30:236-238.
77. Li X, Zhao D, Liu J, et al. The study on the effects of apolipoprotein E gene polymorphism on serum lipids and its frequency distribution in Beijing natural population. J Cardiovascul Pulmon Dis (Chin). 2002;21:193-197.
78. Liou FE. Measurement of apolipoprotein E genetic variation and serum lipid levels. Chin J Contemp Pediatr (Chin). 2001;3:667-668.
79. Long SY, Zhang XM, Fu MH, Xu YH, Liu BW. Relationship of ApoE gene polymorphism with sub-classes of serum high-density lipoprotein in hyperlipidemia [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004;21(6):615-617.
80. Ng MC, Wang Y, So WY, et al. Ethnic differences in the linkage disequilibrium and distribution of single-nucleotide polymorphisms in 35 candidate genes for cardiovascular diseases. Genomics. 2004;83(4):559-565.
81. Ritter MM, Gewitsch J, Richter WO, Geiss HC, Wildner MW, Schwandt P. Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein(a). Atherosclerosis. 1997;131(2):243-248.
82. Rodrigues MO, Fonseca A, Matias DC, et al. APOE genotypes and dyslipidemias in a sample of the Portuguese population. Clin Chem Lab Med. 2005;43(9):907-912.
83. Rump P, Mensink RP, Hornstra G. Interaction between a common variant of the cholesteryl ester transfer protein gene and the apolipoprotein E polymorphism: effects on plasma lipids and lipoproteins in a cohort of 7-year-old children. Nutr Metab Cardiovasc Dis. 2002;12(6):317-324.
84. Salah D, Bohnet K, Gueguen R, Siest G, Visvikis S. Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J Lipid Res. 1997;38(5):904-912.
85. Sorli JV, Corella D, Frances F, et al. The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European population. Clin Chim Acta. 2006;366(1-2):196-203.
86. Tan CE, Tai ES, Tan CS, et al. APOE polymorphism and lipid profile in three ethnic groups in the Singapore population. Atherosclerosis. 2003;170(2):253-260.
87. Tremblay AJ, Bergeron J, Gagne JM, Gagne C, Couture P. Influence of apolipoprotein E genotype on the reliability of the Friedewald formula in the estimation of low-density lipoprotein cholesterol concentrations. Metabolism. 2005;54(8):1014-1019.
88. Wang X, Wang GQ, Yang CR, Li X. Apolipoprotein E gene polymorphism and its association with human longevity in the Uygur nationality in Xinjiang. Chin Med J (Engl). 2001;114(8):817-820.
89. Xiang W, Zhao S, Peng D. Apolipoprotein E polymorphism and plasma lipid, lipoprotein, apolipoprotein levels in 291 children of Changsha [in Chinese]. Hunan Yi Ke Da Xue Xue Bao. 1999;24(3):232-236.
90. Xie YH. Epsilon 4: a genetic factor susceptible to hypercholesterolemia. Zhonghua Yi Xue Za Zhi (Chin). 1989;69:585-587.
91. Yan SK, Zhou X, Ha DW. Influence of apolipoprotein E gene polymorphism on lipids, apolipoproteins and Lp(a) in Han Chinese. Bas Med Sci Clin (Chin). 1998;18:48-52.
92. Ye S, Dunleavey L, Bannister W, et al. Independent effects of the -219 G>T and epsilon 2/ epsilon 3/ epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study. Eur J Hum Genet. 2003;11(6):437-443.
93. Yuan RY, Liang SL, Mai YM, Chui RZ. The study of interrelationship between apolipoprotein E alleles polymorphism and coronary heart disease. Chin J Cardiol. 1998;3:320-322.
94. Zak I, Balcerzyk A, Sarecka B, Niemiec P, Ciemniewski Z, Dylag S. Contemporaneous carrier-state of two or three "proatherosclerotic" variants of APOE, ICAM1, PPARA, and PAI-1 genes differentiate CAD patients from healthy individuals. Clin Chim Acta. 2005;362(1-2):110-118.
95. Zeng HS, Liu XQ, Wu SQ, Guo ZS, Chen ZY. The effects of apolipoprotein E gene polymorphism on the concentrations of lipids and lipoproteins in Chinese children. Chin J Child Health Care (Chin). 1998;6:83-85.
96. Zhang SM, Cui Y, Fang WH. Effect of genetic variation of apolipoprotein B and apolipoprotein E genetic polymorphism on coronary artery disease. Chin J Pract Intern Med (Chin). 2003;23:475-477.
97. Zhang ST, Liu ZX, Chen WF. The effects of ApoE gene polymorphism and serum lipid levels in the newborn baby. Xin Sheng Er Ke Za Zhi (Chin). 1998;13:241-243.
98. Zhao M, Zhao CS, Bai XJ, Zhao YY, Zhang M, Chen CX. Role of lipid levels and gene polymorphisms of apolipoprotein E in siblings with family history of premature coronary heart disease. J Chin Med Uni (Chin). 2002;31:6-8.
99. Zhu CL, Zhou X, Liu F, Hu HL. The relationship between polymorphisms of apolipoprotein E gene and serum lipid levels. Chin J Arterioscl (Chin). 2005;13:203-206.
100. Zhu JH, Pan M, Wang HM, Sun CL, Liu ZH. The effect of apolipoprotein E polymorphism on serum lipids, lipoproteins, and apolipoproteins variation. J Clin Cardiol (Chin). 2002;18:63-65.
101. Zhu JY, Gao HQ, Zhou YK, et al. The association of apolipoprotein E and coronary heart disease. Clin Med J Chin (Chin). 2002;9:224-226.
102. Baitasova NB, Rysmendiev AZ, Shchuratova SG. Apolipoprotein genes in patients with ischemic heart disease [in Russian]. Klin Med (Mosk). 2001;79(12):19-21.
103. Benes P, Muzik J, Benedik J, et al. Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male caucasians. Mol Genet Metab. 2000;69(2):137-143.
104. Cao W, Chen F, Teng L, Wang S, Fu S, Zhang G. The relationship between apolipoprotein E gene polymorphism and coronary heart disease and arteriosclerotic cerebral infarction [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 1999;16(4):249-251.
105. Corbo RM, Vilardo T, Ruggeri M, Gemma AT, Scacchi R. Apolipoprotein E genotype and plasma levels in coronary artery disease: a case-control study in the Italian population. Clin Biochem. 1999;32(3):217-222.
106. Cumming AM, Robertson FW. Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet. 1984;25(4):310-313.
107. Dzimiri N, Meyer BF, Hussain SS, Basco C, Afrane B, Halees Z. Relevance of apolipoprotein E polymorphism for coronary artery disease in the Saudi population. Arch Pathol Lab Med. 1999;123(12):1241-1245.
108. Eichner JE, Kuller LH, Orchard TJ, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71(2):160-165.
109. Eto M, Watanabe K, Makino I. Increased frequencies of apolipoprotein epsilon 2 and epsilon 4 alleles in patients with ischemic heart disease. Clin Genet. 1989;36(3):183-188.
110. Feng S, Wang H, Wang Q, Tian JL. Analysis of apolipoprotein E gene polymorphisms in elderly coronary heart disease. Geriatr Health Care (Chin). 2005;11:174-176.
111. Garcés C, Maicas C, Grande R, et al. epsilon3epsilon4 genotype as risk factor of myocardial infarction in middle-aged people in Spain. Dis Markers. 2005;21(3):153-156.
112. Weber M, McNicoll S, Marcil M, et al. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. Can J Cardiol. 1997;13(3):253-260.
113. Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian Simvastatin Survival Study. Circulation. 2000;101(12):1366-1371.
114. Gong W, Peng S, Peng J, Wang J. Association of geriatric myocardial infarction and apolipoprotein E gene polymorphism. Applied Geriatr (Chin). 2000;14:131-133.
115. Guan SM, Li W, Zhang YH, Qi BL, Ke QM. Relativity between apolipoprotein E genotype, level of blood lipids, and lipoprotein in patients with coronary heart disease. J Clin Cardiol (Chin). 2002;18:166-168.
116. Hergenc G, Taga Y, Emerk K, Cirakoglu B. Apolipoprotein E genotyping in Turkish myocardial infarction survivors and healthy controls. J Biomed Sci. 1995;2(1):46-49.
117. Kim IJ, Hong BK, Lee BK, et al. Apolipoprotein E polymorphism in non-diabetic patients with acute coronary syndrome. Yonsei Med J. 1999;40(4):377-382.
118. Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem. 1986;32(5):778-781.
119. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358(9276):115-119.
120. Kuusi T, Nieminen MS, Ehnholm C, et al. Apoprotein E polymorphism and coronary artery disease: increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis. 1989;9(2):237-241.
121. Attila G, Acarturk E, Eskandari G, et al. Effects of apolipoprotein E genotypes and other risk factors on the development of coronary artery disease in Southern Turkey. Clin Chim Acta. 2001;312(1-2):191-196.
122. Lehtinen S, Lehtimaki T, Sisto T, et al. Apolipoprotein E polymorphism, serum lipids, myocardial infarction, and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis. 1995;114(1):83-91.
123. Li HM, Pan M, Liang S, Wang HM, Chua ZC, Zhu HJ. Effect of apolipoprotein E, angiotensin-converting enzyme gene on coronary heart disease in Chinese population. Chin J Mod Med (Chin). 2003;13:35-37.
124. Li W, Guan SM, Qi BL, Ke QM, Zhang HP. The clinical significance of the detection of apolipoprotein E polymorphism for coronary heart disease in the elderly. population. Chin J Geriatr (Chin). 2003;22:214-217.
125. Liu XC, Peng HY, Qin GF. The relationship of ApoE polymorphisms with the serum concentration of ApoE in coronary heart disease. Shanghai J Med Lab Sci (Chin). 2003;18:36-39.
126. Liao MZ, Jian BF, Xu CH, Xu CH, Hu FG, Huang XR. The study of relationship between apolipoprotein E polymorphism and coronary heart disease. Pract Prev Med (Chin). 2004;11:691-693.
127. Liu HX, Cao LC, Fu GL, Du PeG, Fu SB. Correlation between apolipoprotein E gene polymorphism and coronary heart disease and cerebral thrombosis. China J Mod Med (Chin). 1999;9:78-80.
128. Liu S, Ma J, Ridker PM, Breslow JL, Stampfer MJ. A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis. 2003;166(2):323-329.
129. Lu YS, Wu WJ, Xu X, Zhuang QQ, Wu MP, Mei MZ. Relationship between apolipoprotein E polymorphisms, serum lipid levels and myocardial infarction. Chin J Arterioscl (Chin). 1999;7:110-112.
130. Yang Z, Zhu T, Ma G, et al. Apolipoprotein E polymorphism in the early onset of coronary heart disease. Chin Med J (Engl). 2001;114(9):983-985.
131. Mamotte CD, Burke V, Taylor RR, van Bockxmeer FM. Evidence of reduced coronary artery disease risk for apolipoprotein epsilon2/3 heterozygotes. Eur J Intern Med. 2002;13(4):250-255.
132. Damaraju S, Yu QT, Safavi F, Marian AJ. Apolipoprotein epsilon 4 is not a genetic risk factor for coronary artery disease or restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995;75(16):1181-1183.
133. Marshall HW, Morrison LC, Wu LL, et al. Apolipoprotein polymorphisms fail to define risk of coronary artery disease: results of a prospective, angiographically controlled study. Circulation. 1994;89(2):567-577.
134. Biggart S, Chin D, Fauchon M, et al. Association of genetic polymorphisms in the ACE, ApoE, and TGF beta genes with early onset ischemic heart disease. Clin Cardiol. 1998;21(11):831-836.
135. Kumar P, Luthra K, Dwivedi M, Behl VK, Pandey RM, Misra A. Apolipoprotein E gene polymorphisms in patients with premature myocardial infarction: a case-controlled study in Asian Indians in North India. Ann Clin Biochem. 2003;40(Pt 4):382-387.
136. Mustafina OE, Shagisultanova EI, Tuktarova IA, Khusnutdinova EK. Polymorphism of the apolipoprotein E gene and the risk of myocardial infarction [in Russian]. Mol Biol (Mosk). 2002;36(6):978-984.
137. Niao Q, Liang ZD, Hu SH, Li NM, Lu XM. The relationship of apolipoprotein E gene polymorphism and coronary heart disease in Guang Xi, Zhuang population. J Sichuan Univ (Med Sci Edition) (Chin). 2004;35:285-286.
138. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis. 2001;154(3):529-537.
139. Pan YY, Hu J, Li Dong X, Pan ZH, Wang YC. Effects of ApoE polymorphism on plasma lipid levels and coronary disease. J Clin Intern Med (Chin). 2001;18:267-269.
140. Baroni MG, Berni A, Romeo S, et al. Genetic study of common variants at the ApoE, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. BMC Med Genet. 2003;4:8-14.
141. Peng J, Gong WX, Peng S, Wang J, Shi L, Lin XF. Effect of apolipoprotein E gene polymorphism on plasma lipid levels and association with coronary heart disease. Chin J Arterioscl (Chin). 1999;7:307-310.
142. Ranjith N, Pegoraro RJ, Rom L, Rajput MC, Naidoo DP. Lp(a) and apoE polymorphisms in young South African Indians with myocardial infarction. Cardiovasc J S Afr. 2004;15(3):111-117.
143. Salazar LA, Hirata MH, Giannini SD, et al. Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease. Clin Chim Acta. 2000;300(1-2):139- 149.
144. Yan S, Zhou X, Lin Q, Song Y. Association of polymorphism of apolipoprotein E gene with coronary heart disease in Han Chinese. Chin Med J (Engl). 1999;112(3):224-227.
145. Stengård JH, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Genotypes with the apolipoprotein epsilon4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men. Hum Genet. 1996;97(5):677-684.
146. Talmud PJ, Lewis SJ, Hawe E, et al. No APOEepsilon4 effect on coronary heart disease risk in a cohort with low smoking prevalence: the Whitehall II study. Atherosclerosis. 2004;177(1):105-112.
147. Talmud PJ, Stephens JW, Hawe E, et al. The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet. 2005;69(Pt 6):613-622.
148. Utermann G, Hardewig A, Zimmer F. Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet. 1984;65(3):237-241.
149. Wang C, Zhou X, Ye S, et al. Combined effects of apoE-CI-CII cluster and LDL-R gene polymorphisms on chromosome 19 and coronary artery disease risk. Int J Hyg Environ Health. 2006;209(3):265-273.
150. Wang CH, Zhou X, Zhou GD, et al. Genetic association of apoE and apoCI gene polymorphisms with coronary heart disease [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25(11):982-985.
151. Wang XL, McCredie RM, Wilcken DE. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol. 1995;15(8):1030-1034.
152. Wu QP, Li PY, Wu SQ, et al. Study of apolipoprotein E gene polymorphism and coronary heart disease in the elderly. Chin J Clin Rehabilitation (Chin). 2002;6:74-75.
153. Wu QP, Li W, Li PY, Shen QL. Polymorphism of apolipoprotein E gene angiotensin-1 converting enzyme in the elderly with hypertension and coronary heart disease. Chin J Clin Rehabilitation (Chin). 2005;9:82-83.
154. Wu XL, Long J. The relations between apolipoprotein E polymorphism and diseases. J Navy Med (Chin). 2000;21:32-34.
155. Yamamura T, Tajima S, Miyake Y, et al. Hyperlipoproteinemia as a risk factor for ischemic heart disease. Jpn Circ J. 1990;54(4):448-456.
156. Yang SL, He BX, He ZY, Zhan H, Hong XF, Zou YC. Relation between extent of coronary heart disease and apolipoprotein E gene polymorphisms. J Clin Cardiol (Chin). 2003;19:134-137.
157. Yang SL, He BX, He ZY, Zhan H, Hong XF, Zou YC. Apolipoprotein E gene polymorphisms and risk of coronary heart disease in Chinese Xinjiang Uygur and Han populations. Chin J Arteroscler (Chin). 2003;11:429-433.
158. Yang ZJ, Zhu TB, Yang B, et al. Study of apoE gene polymorphism in coronary heart disease. Jiangsu Med J (Chin). 2000;26:269-270.
159. Zhang GB, Chen HZ, Jiang ZW, Wen QZ, Lu YS, Zhuang WY. The relationship of apolipoprotein E gene polymorphism to coronary artery disease Chin J Arterioscl (Chin). 2001;9:310-312.
160. Zhang HQ, Yu K, Huang WJ, Lin G, Shi CG. To explore the relativity of apolipoprotein B and E gene polymorphisms with coronary heart disease and hypertension. Prev Treat Cardio-Cerebral-Vascular Dis (Chin). 2002;2:20-22.
161. Zhang YL, You K, Zhang LH, et al. Effect of apolipoprotein E polymorphism on serum lipids, coronary heart disease and carotid artery atherosclerosis. Chin J Cardiol (Chin). 1998;26:443-447.
162. Zhu DM, Chen ZJ, Zeng WW, et al. Study on the relationship between apolipoprotein E gene polymorphism and coronary heart disease. Chin Circ J (Chin). 1997;12:347-350.
163. Zhu TB, Yang ZJ, Ma GS, et al. The study of apolipoprotein E gene polymorphism in patients with coronary heart disease. Chin Circ J (Chin). 2000;15:221-222.
164. Zou YC, Hong XF, Hu DY, et al. Relationship between apolipoprotein E gene polymorphisms and coronary heart disease. Chin J Arterioscl (Chin). 2005;13:355-358.
165. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol. 1996;16(10):1250-1255.
166. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
167. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006;31(8):445-454.
168. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257(5):2518-2521.
169. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res. 1990;31(8):1503-1511.
170. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
171. Larson IA, Ordovas JM, DeLuca C, Barnard JR, Feussner G, Schaefer EJ. Association of apolipoprotein (Apo)E genotype with plasma apoE levels. Atherosclerosis. 2000;148(2):327-335.
172. Frikke-Schmidt R, Nordestgaard BG, Gerholm-Larsen B, Schnohr P, Tybjaerg-Hansen A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res. 2000;41(11):1812-1822.
173. März W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Eur Heart J. 2004;25(23):2109-2119.
174. Bioletto S, Fontana P, Darioli R, James RW. Apolipoprotein E polymorphism and the distribution profile of very low density lipoproteins: an influence of the E4 allele on large (Sf > 60) particles. Atherosclerosis. 1998;138(1):207-215.
175. Chasman DI, Kozlowski P, Zee RY, Kwiatkowski DJ, Ridker PM. Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun. 2006;7(3):211-219.
176. Colton CA, Brown CM, Vitek MP. Sex steroids, APOE genotype and the innate immune system. Neurobiol Aging. 2005;26(3):363-372.
177. Brown CM, Wright E, Colton CA, Sullivan PM, Laskowitz DT, Vitek MP. Apolipoprotein E isoform mediated regulation of nitric oxide release. Free Radic Biol Med. 2002;32(11):1071-1075.
178. Elosua R, Demissie S, Cupples LA, et al. Obesity modulates the association among APOE genotype, insulin, and glucose in men. Obes Res. 2003;11(12):1502-1508.
179. Ordovas JM, Schaefer EJ. Genes, variation of cholesterol, and fat intake and serum lipids. Curr Opin Lipidol. 1999;10(1):15-22.
180. Weggemans RM, Zock PL, Ordovas JM, Pedro-Botet J, Katan MB. Apoprotein E genotype and the response of serum cholesterol to dietary fat, cholesterol and cafestol. Atherosclerosis. 2001;154(3):547-555.
181. Maitland-van der Zee AH, Jukema JW, Zwinderman AH, et al. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol. 2006;61(3):327-331.
182. Keavney B, Parish S, Palmer A, et al. Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E epsilon2/epsilon3/epsilon4 genotype. Lancet. 2003;361(9355):396-398.
183. Ioannidis JP, Gwinn M, Little J, et al. A road map for efficient and reliable human genome epidemiology. Nat Genet. 2006;38(1):3-5.